Oric (ORIC) Director Richard Heyman Sells Shares, Exercises Options

What Happened
Richard A. Heyman, a director of Oric Pharmaceuticals (ORIC), reported multiple transactions dated July 24, 2026. He exercised/options activity included acquiring 3,500 shares by exercising options at $1.60/share (total cash paid $5,600). He also reported two open‑market sales the same day: 7,000 shares at $12.02 ($84,140) and 6,100 shares at $12.02 ($73,322), for combined proceeds of $157,462. The filing also records a derivative conversion/related derivative line for 3,500 shares at $0.00.

Key Details

• Transaction date: 2026-07-24; Form 4 filed 2026-07-28 (timely filing).
• Sales: 7,000 shares @ $12.02 ($84,140) and 6,100 shares @ $12.02 ($73,322) — total proceeds $157,462. (Code S = Sale)
• Option exercise: 3,500 shares exercised @ $1.60 ($5,600). (Code M = Exercise/Conversion of derivative)
• Additional derivative line: 3,500 shares reported as disposed @ $0.00 (reported on the form).
• Footnotes: Sales were executed under a Rule 10b5‑1 trading plan (F1). Shares are held of record by RAHD Capital, LLC; Heyman has voting and investment power (F2). The optioned shares were fully vested and immediately exercisable (F3).
• Shares owned after the transactions: not specified in the provided data.

Context
The filings show a same‑day exercise of options plus open‑market sales. The sales were carried out under a preplanned 10b5‑1 arrangement, which is commonly used to automate insider selling and can indicate routine portfolio management rather than a new opinion on company prospects. The exercise at $1.60/share was relatively small cash outlay versus the proceeds from the sales; the filing does not state whether the sold shares included the exercised shares.